In swine nursery production, where post-weaning enterotoxigenic E. coli F4 (K88) scours is a recurring batch-level problem, Shanhua Huangqin Extract Powder Veterinary Grade API is incorporated as a granulated premix rather than as raw fine powder because the native extract carries electrostatic dust losses, poor flow through dosing augers, and a bitter flavonoid aglycone fraction that triggers feed refusal at high inclusion. The extract is standardized for this application to a baicalin content of 20.0–23.5% by HPLC against the supplier’s certificate of analysis. Batch-to-batch variation in air-dried Scutellaria baicalensis root material has been observed in the range of 18.5–23.6% baicalin; downstream production is therefore adjusted to baicalin equivalence rather than extract weight whenever assay results fall below 18.0%. In a nursery feed line using a 500 kg high-shear granulator with a 2.0 mm sieve and a 100 kg ribbon blender, the extract is wet-granulated with an aqueous 2% hydroxypropyl methylcellulose binder at a spray rate of 0.4 kg/min, dried at an inlet air temperature of 60°C in a fluid-bed dryer to a final moisture content of ≤5.0%, and sieved to a particle size window of 125–300 µm. This granular fraction is then mixed with maltodextrin or corn starch as a carrier to form a 10% extract premix, which is metered into complete creep feed at 30–50 kg premix per metric ton, equivalent to 3–5 kg extract per metric ton or 0.3–0.5% w/w of final feed. Controlled piglet challenge models indicate that response against F4 challenge becomes distinguishable from control above 2 kg/t extract, while feed refusal episodes have been reported on nursery lines above 6 kg/t, particularly in mash rather than pelleted diets. The terminal product types are 5% or 10% extract microgranule premixes in 25 kg multi-wall paper bags with inner polyethylene liners, and 100 g oral granule sachets for direct administration to small suckling pigs. Compliance is maintained against the Veterinary Pharmacopoeia of the People’s Republic of China 2020 extract-powder monograph, with heavy metal limits assessed by GB/T 13081, total aerobic microbial count by GB/T 13093, and mycotoxin absence verified on each production lot. Because Scutellaria extract is not listed as a zootechnical feed additive under Reg (EC) 1831/2003 in the European Union, downstream users in EU markets must apply national botanical feed additive or veterinary medicinal frameworks, and a licensed withdrawal period is mandatory only where the product is registered as a veterinary medicinal product in the destination country.

How does a veterinary herbal extract survive continuous avian drinking water lines at pH 5.5?

The raw extract presents an immediate formulation problem in poultry drinking water because baicalin is poorly dispersed under the acidic conditions of many nipple drinker lines. Water systems with a pH in the range of 5.0–6.0 promote precipitation of the aglycone fraction, leading to sedimentation in low-flow components and clogging of in-line filters. To manage this, the extract is spray-dried with a sodium carbonate and maltodextrin carrier system to a bulk density of 0.45–0.55 g/mL and a particle size of ≤0.425 mm. The resulting water-soluble powder is dispersed at 5 g in 1 L deionized water at 25°C with 100 rpm stirring; the dispersion should pass a 0.150 mm screen within 5 min. This is not a true solution because residual aglycones remain, so a ≤74 µm in-line filter is installed before the nipple drinker manifold. For medicated water application under veterinary prescription, a stock solution is prepared at 10% w/v extract in water at 40–45°C and then dosed through a proportional medicator at 1:50 to achieve a final drinking water concentration of 0.4–0.8 g/L in broiler enteric or respiratory disease episodes. At pH 5.0 in a commercial nipple line, unformulated extract showed visible precipitation at 0.6 g/L after 4 h; the bicarbonate-buffered formulation maintained a pH of 6.8–7.2 and remained free of settled floc for 8 h. The extract should not be combined with strong oxidizing drinking water disinfectants at free chlorine levels above 1 mg/L because electrophilic substitution on the flavone ring reduces baicalin recovery; when chlorination is required, oxidant contact should be completed before the extract stock solution is introduced at the medicator. Terminal product types are water-soluble powder in 100 g and 1 kg PET jars, and in-line concentrated solution in 1 L HDPE bottles. The manufacturing plant should operate under FAMI-QS for specialty feed ingredients and ISO 22000 for feed safety management, while medicated water applications fall under veterinary medicine authorization in many jurisdictions; downstream formulators must confirm that the active ingredient is permitted for the target species and that the water-soluble formulation meets USP <711> dissolution criteria where applicable.

Where calf scours recurs across multiple batches in a calf-rearing unit, a buffered oral drench containing the extract is used as an adjunct to fluid and electrolyte therapy rather than as a feed-administered powder, because direct mixing of the extract into milk replacer at temperatures above 40°C has resulted in phase separation at concentrations exceeding 2% w/v. The drench is formulated at 5.0 g extract per 100 mL, equivalent to 5% w/v, with the extract standardized to 20% baicalin. Administration is commonly cited as 1 mL/kg body weight twice daily, delivering approximately 10 mg baicalin/kg body weight per dose; however, published data for this exact dose in preruminant calves is limited, and dosing is frequently derived from piglet and poultry challenge studies. The drench vehicle contains disodium hydrogen phosphate and citric acid to buffer pH at 6.8, 0.1% sodium benzoate as preservative, and 0.5% sodium carboxymethyl cellulose as suspending agent. The liquid is processed in a high-shear mixer at 3,000 rpm for 15 min until complete particle wetting, then homogenized at 1,000 rpm before filling into 1 L or 5 L HDPE drench jugs. Terminal product types include oral drench and 250 mL multidose oral paste guns. The drench is controlled under the VPA 2020 oral liquid monograph for microbial and heavy metal limits, and production is governed by current veterinary drug GMP. In food-producing ruminants, a licensed withdrawal period is mandatory; because rumen microbial degradation of baicalin is significant, use is restricted to preruminant calves or abomasal paste administration, and no use should be considered in lactating dairy cattle producing milk for human consumption unless the product is explicitly approved for that class.

Aquafeed stability, extrusion shear, and the baicalin retention window

The first point of failure in aquafeed applications is the twin-screw or single-screw extrusion step, where barrel temperatures commonly exceed 85°C and residence time under mechanical shear can lower baicalin recovery relative to the unextruded mix. Published thermal degradation data for baicalin in extruded aquafeed specifically is limited; however, phytochemical stability studies indicate significant degradation above 80°C and under alkaline pH, so post-pelleting vacuum coating is preferred over pre-extrusion mixing. For finished fish feed, the extract is dispersed in fish oil or soybean lecithin at 45–50°C and sprayed onto extruded pellets in a vacuum coater at −0.06 MPa for 20 min, targeting an oil uptake of 2–3% w/w. The extract addition rate is 5–10 g per kg finished feed, equivalent to 0.5–1.0% w/w. Terminal product types are extruded sinking pellets for tilapia and carp at 2.0 mm, shrimp crumbles at 0.5–1.0 mm, and top-coated premix in 25 kg sacks. An alternative immersion bath method for fingerlings uses 5 g/L extract for 10–15 min with aeration, but this method imposes a chemical oxygen demand and is less common outside hatchery systems. Compliance is maintained under HACCP aligned with Codex Alimentarius CXC 52-2003 and ISO 22000; in the United States, a botanical extract used for disease claim in aquaculture feed would trigger medicated feed requirements, and Scutellaria extract is not an AAFCO-defined feed ingredient, so end users must operate only where national aquaculture veterinary rules allow. The vacuum-coating operation must ensure that the extract-oil suspension remains below 50°C during the entire recirculation loop; batch lines with slow recirculation through unjacketed piping have shown localized cooling and sedimentation at the spray nozzle, producing under-dosed pellets.

Clinically, canine atopic dermatitis and feline gingivostomatitis have led some veterinary pharmacies to compound the extract into low-dose tablet and capsule formats; however, published controlled trials in companion animals remain sparse, and the available evidence is largely extrapolated from rodent and porcine inflammation models. The extract is formulated into 50 mg, 100 mg, and 250 mg tablet strengths standardized to 20–23% baicalin by HPLC. Compounding pharmacists frequently use 5–10 mg extract/kg body weight q12h, but this is not a licensed dose and must be adjusted by the supervising veterinarian. For direct compression, the formulation consists of microcrystalline cellulose, croscarmellose sodium, colloidal silica, and magnesium stearate; batches with poor flow or high residual moisture are instead wet-granulated with a 5% povidone binder in a high-shear granulator, dried to moisture below 3.0%, and compressed to a hardness of 50–70 N. Tablet disintegration is controlled to ≤15 min by USP <701>, and content uniformity is maintained at 85–115% of labeled baicalin by USP <905>. Terminal product types are chewable tablets and capsules in 100 mg and 200 mg capsule strengths. Compliance is conditioned on FDA 21 CFR 530 extralabel use in veterinary medicine; the extract is not an AAFCO-defined pet food ingredient, and in the European Union, veterinary herbal products require national registration before lawful placing on the market. Because cats may exhibit salivation and head shaking due to the bitter aglycone fraction, palatability often requires encapsulation rather than chewable administration.

When a lipophilic flavonoid extract enters a sterile injectable line

A sterile aqueous injectable formulation derived from a plant extract requires over-engineering because the extract contains polysaccharides, tannins, and residual particulates that can form haze or contribute to pyrogen load. The production process begins with solubilization of the API in water-for-injection at 70°C at a concentration of 20 g/L extract, equivalent to 4 g/L baicalin. The solution is adjusted to pH 6.5 with sodium hydroxide and held at 100°C for 30 min to reduce microbial load and precipitate thermolabile polysaccharides, followed by cooling to 50°C and sequential filtration through 0.45 µm and 0.2 µm polysulfone filters. The filtrate is filled into 10 mL brown glass ampoules under nitrogen to minimize oxidation of baicalein and wogonin. Each 10 mL ampoule contains 200 mg extract; it is used as a compounded injectable adjunct in large-animal febrile respiratory cases under veterinary supervision, but no harmonized clinical dosing exists across jurisdictions. Terminal product types are 10 mL ampoules and 50 mL multi-dose vials; lyophilized powder for reconstitution may be offered if a lecithin-free formulation is required.

Active ingredient manufacture for the injectable grade is performed under ICH Q7 and EU GMP Part II, while the finished sterile veterinary medicinal product is prepared under GMP Annex 1. The API must be certified as veterinary-grade by the competent authority in the destination market, and terminal sterilization is not a substitute for bioburden control because thermal degradation of baicalin accelerates above 100°C under aqueous conditions. The operational boundary is therefore strict: the solution may be held at 100°C for not more than 30 min, and post-filtration holding time before filling should remain below 2 h to avoid oxidative loss of the aglycone fraction.